GGrantIndex
Sort

261,768 grants matching gene therapy

National Gene Vector Biorespository and Coordinating Center at Indiana University

$987,591
Kenneth G Cornetta · Indiana University Indianapolis · P40 · FY2008 · RR

Integrative Analysis Core

$987,546
Nicholas Joseph Schork · Translational Genomics Research Inst · U19 · FY2025 · AG

Telomeres and Telomerase in Cancer

$987,528
Carol W Greider · Johns Hopkins University · R35 · FY2017 · CA

Red Cell Biology

$987,510
David M. Bodine · National Human Genome Research Institute · ZIA · FY2019 · HG

Molecular prostheses for mitochondrial disorders

$987,482
Vamsi Krishna Mootha · Massachusetts General Hospital · R01 · FY2013 · GM

Improving marginal allograft outcomes through cell junction stabilization in transplantation

$987,481
Christina Grek · Xequel Bio, Inc. · R44 · FY2022 · DK

Development and Use of Network Infrastructure for High-Throughput GWA Studies

$987,473
Eric B Larson · Kaiser Foundation Health Plan Of Washington · U01 · FY2008 · HG

SIRT1 in Skeletal Muscle Development, Regeneration, and Atrophy

$987,322
Vittorio Sartorelli · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2019 · AR

Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings

$987,292
Manijeh N Goldberg · Privo Technologies, Llc · R44 · FY2023 · CA

Ocular Gene Therapy

$987,243
Zhijian Wu · National Eye Institute · ZIA · FY2015 · EY

A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis

$987,225
Gary Fanger · Rise Therapeutics, Llc · R44 · FY2024 · AG

Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)

$987,185
Vikas R. Dharnidharka · Washington University · U01 · FY2023 · CA

The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx) Project 2: Preclinical Model for Antiepileptogenic Therapy Screening in Post-traumatic Epilepsy

$987,181
Aristea S Galanopoulou · University Of Southern California · U54 · FY2019 · NS

Telomere Diseases

$987,089
Neal S Young · National Heart, Lung, And Blood Institute · ZIA · FY2015 · HL

Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer

$987,088
Jean Zhao · Dana-Farber Cancer Inst · R35 · FY2022 · CA

Safety and Tolerability Studies for an Anti-Fibrin P2 Monoclonal Antibody for the Treatment of Alzheimer's Disease

$987,080
Jeffrey Stavenhagen · Therini Bio, Inc. · U01 · FY2021 · AG

From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma

$987,000
Riccardo Dalla-Favera · Columbia University Health Sciences · R35 · FY2025 · CA

Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level

$987,000
Andrea Califano · Columbia University Health Sciences · R35 · FY2022 · CA

From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma

$987,000
Riccardo Dalla-Favera · Columbia University Health Sciences · R35 · FY2023 · CA

Chromosomal Proteins and Chromosomal Functions

$986,978
Michael Bustin · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Extracellular non-coding RNA biomarkers of hepatocellular cancer

$986,936
Tushar Patel · Mayo Clinic Jacksonville · UH3 · FY2016 · TR

IND-Enabling Development of HIV Maturation Inhibitors Formulated for use as either Oral or Long-Acting Parenterally Administered Agents

$986,894
Carl Wild · Dfh Pharma, Inc. · R44 · FY2025 · AI

Mesothelin-targeted immunotoxins in Pancreatic Cancer

$986,847
Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Genetic Susceptibility to Pediatric Glioma inIndividuals and Diverse populations

$986,792
Joseph Leo Wiemels · University Of California, San Francisco · R01 · FY2016 · CA

Studies of the Natural History of Sickle Cell Disease

$986,763
Swee Lay Thein · National Heart, Lung, And Blood Institute · ZIA · FY2023 · HL